Stem cells, a promising and promising approach, have attracted a lot of attention around the world. However, we can't help but ask: how far away are stem cells** from us?
Recently, the Changsha Evening News "Scientific Life" column group interviewed Wang Jian, an expert from the autologous stem cell project team of the Chinese Academy of Engineering.
Judging from the content of the column, the expert advice.
First of all, we need to make it clear that stem cells** are not "universal cells", but "universal cells". Although they have the ability to differentiate in multiple directions, they can differentiate into a variety of cell types, providing the possibility for a wide range of diseases. However, stem cells are not a panacea, and for some diseases, such as cancer, stem cells cannot completely replace the traditional way.
AI assistant creation season
At present, China is accelerating the R&D and approval of stem cell drugs. It is expected that in the next year, China is expected to launch 3 5 stem cell drugs, which will provide more choices for more patients. At the same time, we must also realize that inclusive is the future trend, but it will take time. The cost of stem cells is still high, so it is necessary to work together among enterprises, enterprises and all aspects of society to promote the popularization and application of stem cells.
The following is an overview of domestic drug declarations:
In 2022, CDE accepted 26 clinical applications for stem cell drugs(based on the acceptance number), there are 25 registration applications for Chinese-made Class 1 innovative drugs and 1 registration application for imported Class 1 innovative drugs. The imported stem cell drug is cytopeutics umbilical cord mesenchymal stem cells (neuroncell-ex).
In 2022, the CDE tacitly approved a total of 16 clinical trials of 11 stem cell drugs。Among them, there are 11 mesenchymal stem cells, mesenchymal stem cellsThe use type accounted for 68%.
As of December 31, 2022, the CDE has acquiesced in the aggregateclinical trials involved 20 indications。Among them, the top three are:Arthritis of the knee(7 items).Interstitial lung disease(mainly idiopathic pulmonary fibrosis) (5 items).Graft-versus-host disease(**HD) (4 items). Among them, there are 7 stem cell drugs for knee osteoarthritis, and the stem cell types include:Autologous adipose mesenchymal stem cells(1 kind),Allogeneic adipose mesenchymal stem cells(2 kinds).Umbilical cord mesenchymal stem cells(3 types).Mesenchymal-like cells of human induced pluripotent stem cells**(1 kind),
In addition, stem cells** still need more research and exploration. While stem cells** have achieved some results, there are still many issues that need to be addressed. For example, stem cell segregation, isolation and expansion techniques need to be further improved and refinedThe indications and safety of stem cells** also require more in-depth research and evaluation.
In conclusion, although stem cells are a promising and promising method, we are still a certain distance away. We need more research and exploration to promote the popularization and application of stem cells** and bring good news to more patients. In this process, the joint efforts of enterprises and all aspects of society are indispensable.